Coliseum Capital Management (Director) sold 3,000,000 shares of UTI at $41.40 on 2026-06-08, reducing stake from 3.97M to 971.4K shares (-75.5%).
Coliseum Capital divested a substantial 3,000,000 shares (75.5% of pre-transaction holdings) for $124,200,000.00, leaving a material but minority position of 971.4K shares. The sale occurred at $41.40, above the current price of $39.75 and above the 52-week low of $21.29, though -13.1% from the 52-week high of $45.74. Notably, the insider's prior two buys at UTI (2025-12-03 and 2025-12-05) both generated strong 90-day returns (+52.9% and +38.2% respectively), establishing a pattern of well-timed entry points at this ticker. This large sale, executed after two successful accumulations, represents a material reduction in conviction and should be monitored given the stock's elevated valuation (P/E 50.96) relative to modest recent profitability ($433.0K net income on $221.4M quarterly revenue).